Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Recombinant Viral-like Particles of Parvovirus B19 as Antigen Carriers of Anthrax Protective Antigen

YOJI OGASAWARA, GEORGIOS AMEXIS, HIROKI YAMAGUCHI, SACHIKO KAJIGAYA, STEPHAN H. LEPPLA and NEAL S. YOUNG
In Vivo May 2006, 20 (3) 319-324;
YOJI OGASAWARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGIOS AMEXIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amexis{at}nih.gov
HIROKI YAMAGUCHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SACHIKO KAJIGAYA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHAN H. LEPPLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NEAL S. YOUNG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Viral-like particles (VLPs) of parvovirus B19 were employed as an antigen carrier to present antigenic determinants of Bacillus anthracis. The small-loop peptide and the full-length domain 4 of protective antigen (PA) were chosen as immunogens for presentation on the VLP-capsid surface and subsequent immunization of BALB/c mice. The recombinant VLPs induced anti-PA IgG titers of up to 2.5×104. Neutralization assays showed that the recombinant VLPs elicited neutralizing anti-PA antibody titers of up to 1:400 and showed potential for the prevention of lethal toxin-induced mortality of mouse-macrophage cells (RAW264.7). In post-immune sera, no anti-PA titers were detected against synthetic small-loop peptide. Recombinant VLPs demonstrated the capacity to retain the immunogenicity of the displayed microbial PA-epitopes and elicited robust levels of anti-PA antibody titers. These findings suggest that the recombinant VLPs of parvovirus B19 have potential as an additional tool in the development of sub-unit vaccines.

  • Anthrax
  • parvovirus B19
  • vaccine development
  • viral-like particles
  • VLPs

Footnotes

  • Received April 6, 2006.
  • Accepted April 13, 2006.
  • Copyright © 2006 The Author(s). Published by the International Institute of Anticancer Research.
PreviousNext
Back to top

In this issue

In Vivo
Vol. 20, Issue 3
May-June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recombinant Viral-like Particles of Parvovirus B19 as Antigen Carriers of Anthrax Protective Antigen
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Recombinant Viral-like Particles of Parvovirus B19 as Antigen Carriers of Anthrax Protective Antigen
YOJI OGASAWARA, GEORGIOS AMEXIS, HIROKI YAMAGUCHI, SACHIKO KAJIGAYA, STEPHAN H. LEPPLA, NEAL S. YOUNG
In Vivo May 2006, 20 (3) 319-324;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Recombinant Viral-like Particles of Parvovirus B19 as Antigen Carriers of Anthrax Protective Antigen
YOJI OGASAWARA, GEORGIOS AMEXIS, HIROKI YAMAGUCHI, SACHIKO KAJIGAYA, STEPHAN H. LEPPLA, NEAL S. YOUNG
In Vivo May 2006, 20 (3) 319-324;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Human Parvoviruses
  • Proteasome-Independent Major Histocompatibility Complex Class I Cross-Presentation Mediated by Papaya Mosaic Virus-Like Particles Leads to Expansion of Specific Human T Cells
  • Google Scholar

More in this TOC Section

  • Differential Influence of Morinda citrifolia L. Fruit Juice on the Molecular Composition of Human Platelet Rich Fibrin
  • Establishment of a Step-down FSH Superovulation Protocol in Microminipigs for Zygote Collection
  • Modulating ACVRL1 Expression in HMEC1 Cells as a Simplified In Vitro Model for Hereditary Hemorrhagic Telangiectasia (HHT) Type 2 Studies
Show more Experimental Studies
In Vivo

© 2026 In Vivo

Powered by HighWire